MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Management of neuropsychiatric symptoms in Parkinson’s disease (PD) at the front door

M.A Farooqi, A. Chatterjee (Reading, United Kingdom)

Meeting: MDS Virtual Congress 2020

Abstract Number: 670

Keywords: Behavioral abnormalities, Hallucinations, Parkinsonism

Category: Parkinson's Disease: Neurophysiology

Objective: To ascertain the number of PD patients admitted to the acute hospital with neuropsychiatric symptoms requiring a review by PD specialist, including medicine reconciliation by a pharmacist.

Background: Parkinson’s is a progressive neurodegenerative condition that requires a complex medication regimen. Patients are often admitted to an acute hospital with behavioural problems apathy and depression. This could be precipitated by infections, electrolyte imbalance but often due to complex drug changes. Parkinson’s UK recommends that patients with PD should have an early specialist input.

Method: The numbers of PD patients admitted to the hospital with neuropsychiatric symptoms were identified from medical informatics between the period of Aug 2018 and July 2019. Data was then collected using a proforma and analysed using Microsoft excel.

Results: 40 patients were included, 55% (22/40) were males. The average age was 81 years. 63% (25/40) of patients had Parkinson’s disease dementia. The presenting symptoms inluded 80% (32/40) drowsy/delirium/confusion, 18% (7/40) hallucinations/aggressive behaviour/confusion, and 3% (1/40) agitated/violent. 30% (12/40) of patients had PD medication changes (within 3 months of the admission) prior to admission whilst 25% (10/40) had their PD medication changed during admission. 38% (15/40) of patients were seen by a PD specialist during admission and the average time for review was 4 days. 23% (9/40) patients were referred to the mental health team. 73% (29/40) of patients had medicine reconciliation prior to their discharge. The average time for which was 3 days.

Conclusion: Our data suggest that patients with neuropsychiatric symptoms should be reviewed promptly by a PD specialist on admission to prevent adverse events and provide safe care. As pharmacotherapy plays an important part in the neuropsychiatric symptoms, review by a specialist pharmacist with an interest in movement disorders may be helpful to reduce any delays.  Such pharmacists can work collaboratively with clinicians , PD Nurses and therapists as part of a multidisciplinary team to improve patient outcomes in the acute setting.

References: [1] National Institute for Health and Care Excellence. (2017). Parkinson’s disease in adults (NICE Guideline No.NG71). [2] The Pharmaceutical Journal, September 2017, Vol 299, 7905, online | DOI: 10.1211/PJ.2017.20203618

To cite this abstract in AMA style:

M.A Farooqi, A. Chatterjee. Management of neuropsychiatric symptoms in Parkinson’s disease (PD) at the front door [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/management-of-neuropsychiatric-symptoms-in-parkinsons-disease-pd-at-the-front-door/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/management-of-neuropsychiatric-symptoms-in-parkinsons-disease-pd-at-the-front-door/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley